These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 22843892)

  • 1. Combined effects of lapatinib and cisplatin on colony formation of head and neck squamous cell carcinoma.
    Schrader C; Boehm A; Reiche A; Dietz A; Mozet C; Wichmann G
    Anticancer Res; 2012 Aug; 32(8):3191-9. PubMed ID: 22843892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single tissue samples from head and neck squamous cell carcinomas are representative regarding the entire tumor's chemosensitivity to cisplatin and docetaxel.
    Wichmann G; Horn IS; Boehm A; Mozet C; Tschop K; Dollner R; Dietz A
    Onkologie; 2009 May; 32(5):264-72. PubMed ID: 19420973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneity of epithelial and stromal cells of head and neck squamous cell carcinomas in ex vivo chemoresponse.
    Horn IS; Wichmann G; Mozet C; Dietz A; Dollner R; Tschöp K; Boehm A
    Cancer Chemother Pharmacol; 2010 May; 65(6):1153-63. PubMed ID: 19771432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulation by Monocyte Chemoattractant Protein-1 Modulates the Ex-vivo Colony Formation by Head and Neck Squamous Cell Carcinoma Cells.
    Wichmann G; Körner C; Boehm A; Mozet C; Dietz A
    Anticancer Res; 2015 Jul; 35(7):3917-24. PubMed ID: 26124338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma.
    Kondo N; Tsukuda M; Ishiguro Y; Kimura M; Fujita K; Sakakibara A; Takahashi H; Toth G; Matsuda H
    Oncol Rep; 2010 Apr; 23(4):957-63. PubMed ID: 20204279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simvastatin suppresses head and neck squamous cell carcinoma ex vivo and enhances the cytostatic effects of chemotherapeutics.
    Stoehr M; Mozet C; Boehm A; Aigner A; Dietz A; Wichmann G
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):827-37. PubMed ID: 24562588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hedgehog targeting by cyclopamine suppresses head and neck squamous cell carcinoma and enhances chemotherapeutic effects.
    Mozet C; Stoehr M; Dimitrova K; Dietz A; Wichmann G
    Anticancer Res; 2013 Jun; 33(6):2415-24. PubMed ID: 23749890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
    Wang-Rodriguez J; Lopez JP; Altuna X; Chu TS; Weisman RA; Ongkeko WM
    Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
    Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
    Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cilengitide and Cetuximab Reduce Cytokine Production and Colony Formation of Head and Neck Squamous Cell Carcinoma Cells
    Wichmann G; Cedra S; Schlegel D; Kolb M; Wiegand S; Boehm A; Hofer M; Dietz A
    Anticancer Res; 2017 Feb; 37(2):521-527. PubMed ID: 28179297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced proliferation and colony formation of head and neck squamous cell carcinoma (HNSCC) after dual targeting of EGFR and hedgehog pathways.
    Liebig H; Günther G; Kolb M; Mozet C; Boehm A; Dietz A; Wichmann G
    Cancer Chemother Pharmacol; 2017 Feb; 79(2):411-420. PubMed ID: 28110457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma.
    Mace AT; Harrow SJ; Ganly I; Brown SM
    Acta Otolaryngol; 2007 Aug; 127(8):880-7. PubMed ID: 17763002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro.
    Zhang N; Erjala K; Kulmala J; Qiu X; Sundvall M; Elenius K; Grénman R
    Radiother Oncol; 2009 Sep; 92(3):388-92. PubMed ID: 19447510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo chemosensitivity of head and neck carcinoma to cytostatic drug combinations.
    Dollner R; Granzow C; Neudert M; Dietz A
    Anticancer Res; 2006; 26(2B):1651-5. PubMed ID: 16619587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lupeol suppresses cisplatin-induced nuclear factor-kappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model.
    Lee TK; Poon RT; Wo JY; Ma S; Guan XY; Myers JN; Altevogt P; Yuen AP
    Cancer Res; 2007 Sep; 67(18):8800-9. PubMed ID: 17875721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin resistance of the HNSCC cell line UT-SCC-26A can be overcome by stimulation of the EGF-receptor.
    Mandic R; Rodgarkia-Dara CJ; Krohn V; Wiegand S; Grénman R; Werner JA
    Anticancer Res; 2009 Apr; 29(4):1181-7. PubMed ID: 19414362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck.
    Harrington KJ; El-Hariry IA; Holford CS; Lusinchi A; Nutting CM; Rosine D; Tanay M; Deutsch E; Matthews J; D'Ambrosio C; Turner SJ; Pandeshwara JS; Bourhis J
    J Clin Oncol; 2009 Mar; 27(7):1100-7. PubMed ID: 19171712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer.
    Rodriguez-Pinilla M; Rodriguez-Peralto JL; Hitt R; Sanchez JJ; Ballestin C; Diez A; Sanchez-Verde L; Alameda F; Sanchez-Cespedes M
    Clin Cancer Res; 2004 Dec; 10(24):8486-92. PubMed ID: 15623629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant cisplatin, paclitaxel, and hyperfractionated radiotherapy in locally advanced head and neck cancer: comparison of two different schedules.
    Moreno-Jiménez M; Valero J; López-Picazo JM; Arbea L; Aristu J; Cambeiro M; Alcalde J; Martínez-Monge R
    Am J Clin Oncol; 2010 Apr; 33(2):137-43. PubMed ID: 19786847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy.
    Hitt R; Ciruelos E; Amador ML; Benito A; Sanchez JJ; Ballestin C; Cortes-Funes H
    Eur J Cancer; 2005 Feb; 41(3):453-60. PubMed ID: 15691646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.